QuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript

QuidelOrtho (QDEL) reported Q2 2026 revenue of $630.9 million, up 1.9% constant-currency, with Labs $382.9 million, Immunohematology $134.2 million, and Point of Care $108.2 million. Adjusted EBITDA was $129.3 million (21% growth). China revenue fell 23.3% constant-currency. Full-year 2026 guidance was lowered to $2.52-$2.60 billion revenue and $540-$560 million adjusted EBITDA, with adjusted EPS $0.65-$0.90.

Original reporting
Published Aug 14, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 12:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$QDELBearishHigh
01

Why it matters

Management reported modest constant-currency revenue growth but materially reduced full-year guidance, withdrew free-cash-flow projections, and flagged China IVD pricing guideline uncertainty as already impacting customer inventory behavior. Despite this, adjusted EBITDA and margin expanded, and Point of Care growth remained strong, with Neulixa commercialization expected to gain momentum in the latter half of 2026.

02

Market read

This is a guidance and cash-flow reset with explicit China regulatory-driven demand uncertainty, plus a leverage snapshot, making it actionable for positioning into 2H 2026.

03

What to watch

The cash flow decline includes specific one-time items (termination payment and working-capital needs) and a large Lex acquisition cost; traders should separate recurring cash conversion from these timing effects when reassessing leverage risk.

Relevance 9/10Novelty 9/10Timing: post-market Aug. 6, 2026 earnings call guidance update

Background

The article is a Q2 2026 earnings call transcript for QuidelOrtho, including segment performance, cash flow, leverage, and updated full-year guidance.

Company-level read

Ticker impact

$QDELBearishMedium confidence
Context

QuidelOrtho guided full-year 2026 revenue to $2.52B-$2.60B and cut adjusted EPS to $0.65-$0.90, citing China IVD pricing guideline headwinds.

Expected impact

Near-term downside bias versus prior expectations, with volatility driven by cash conversion and China demand visibility.

Evidence & confidence

The article discloses multiple decision-grade changes: lowered revenue guidance, sharply reduced adjusted EPS range, withdrawn free-cash-flow projections, negative operating cash flow, and net leverage at 4.3x, partially offset by adjusted EBITDA margin expansion and Point of Care growth.

Market effects

Signals broader respiratory testing and China IVD pricing uncertainty, potentially pressuring peers’ near-term demand assumptions and cash-conversion expectations.

China revenue decline and inventory reductions highlight near-term weakness in China IVD-related demand while ex-China growth remains steadier.

Could reinforce a cautious stance on diagnostics names with China exposure and working-capital sensitivity into the 2H respiratory season.

Counterpoint

Point of Care growth (15.7% constant-currency) and 310 bps adjusted EBITDA margin expansion may indicate operating leverage that can offset revenue softness if Neulixa placements accelerate in 2H 2026.

Key entities

  • QuidelOrtho

    Reported Q2 2026 results and lowered full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; highlighted China IVD pricing guideline headwinds and negative operating cash flow.

  • Brian J. Blaser

    CEO who attributed China inventory reductions and a softer respiratory season outlook to proposed Chinese IVD pricing guidelines and early respiratory indicators.

  • Micah Young

    CFO who emphasized improving cash conversion and reducing leverage as primary objectives.

  • Neulixa

    Lex point-of-care molecular diagnostics platform discussed as a commercialization priority expected to gain momentum during the 2H 2026 respiratory season.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.